One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption

被引:79
作者
Varela, Aurore [1 ]
Chouinard, Luc [1 ]
Lesage, Elisabeth [1 ]
Smith, Susan Y. [1 ]
Hattersley, Gary [2 ]
机构
[1] Charles River Labs, Montreal, PQ, Canada
[2] Radius Hlth Inc, Waltham, MA USA
关键词
ABALOPARATIDE; PTHrP; ANABOLIC AGENTS; BONE FORMATION; OSTEOPOROSIS; HORMONE-RELATED PEPTIDE; INTERMITTENT-PARATHYROID-HORMONE; RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; SCLEROSTIN ANTIBODY; MINERAL DENSITY; OSTEOBLAST LINEAGE; ANABOLIC ACTIVITY; DEFICIENT MICE; CORTICAL BONE;
D O I
10.1002/jbmr.3003
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Abaloparatide is a novel 34-amino acid peptide selected to be a potent and selective activator of the parathyroid hormone receptor (PTH1R) signaling pathway with 41% homology to PTH(1-34) and 76% homology to PTHrP(1-34). A 12-month treatment study was conducted in osteopenic ovariectomized (OVX) rats to characterize the mechanisms by which abaloparatide increases bone mass. Sprague-Dawley (SD) rats were subjected to OVX or sham surgery at age 6 months and left untreated for 3 months to allow OVX-induced bone loss. Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n=18) or abaloparatide at 1, 5, or 25g/kg/d (n=18/dose level) for 12 months. Sham controls (n=18) received vehicle daily. Bone densitometry and biochemical markers of bone formation and resorption were assessed longitudinally, and L-3 vertebra and tibia were collected at necropsy for histomorphometry. Abaloparatide increased biochemical bone formation markers without increasing bone resorption markers or causing hypercalcemia. Abaloparatide increased histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces without increasing osteoclasts or eroded surfaces. Abaloparatide induced substantial increases in trabecular bone volume and density and improvements in trabecular microarchitecture. Abaloparatide stimulated periosteal expansion and endocortical bone apposition at the tibial diaphysis, leading to marked increases in cortical bone volume and density. Whole-body bone mineral density (BMD) remained stable in OVX-Vehicle controls while increasing 25% after 12 months of abaloparatide (25g/kg). Histomorphometry and biomarker data suggest that gains in cortical and trabecular bone mass were attributable to selective anabolic effects of abaloparatide, without evidence for stimulated bone resorption. (c) 2016 American Society for Bone and Mineral Research.
引用
收藏
页码:24 / 33
页数:10
相关论文
共 48 条
[1]
Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development [J].
Amizuka, N ;
Karaplis, AC ;
Henderson, JE ;
Warshawsky, H ;
Lipman, ML ;
Matsuki, Y ;
Ejiri, S ;
Tanaka, M ;
Izumi, N ;
Ozawa, H ;
Goltzman, D .
DEVELOPMENTAL BIOLOGY, 1996, 175 (01) :166-176
[2]
Daily and cyclic parathyroid hormone in women receiving alendronate [J].
Cosman, F ;
Nieves, J ;
Zion, M ;
Woelfert, L ;
Luckey, M ;
Lindsay, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (06) :566-575
[3]
Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis [J].
Cosman, Felicia ;
Eriksen, Erik Fink ;
Recknor, Chris ;
Miller, Paul D. ;
Guanabens, Nuria ;
Kasperk, Christian ;
Papanastasiou, Philemon ;
Readie, Aimee ;
Rao, Hanumantha ;
Gasser, Juerg A. ;
Bucci-Rechtweg, Christina ;
Boonen, Steven .
JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (03) :503-511
[4]
Standardized Nomenclature, Symbols, and Units for Bone Histomorphometry: A 2012 Update of the Report of the ASBMR Histomorphometry Nomenclature Committee [J].
Dempster, David W. ;
Compston, Juliet E. ;
Drezner, Marc K. ;
Glorieux, Francis H. ;
Kanis, John A. ;
Malluche, Hartmut ;
Meunier, Pierre J. ;
Ott, Susan M. ;
Recker, Robert R. ;
Parfitt, A. Michael .
JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (01) :1-16
[5]
Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial [J].
Dempster, David W. ;
Zhou, Hua ;
Recker, Robert R. ;
Brown, Jacques P. ;
Bolognese, Michael A. ;
Recknor, Christopher P. ;
Kendler, David L. ;
Lewiecki, E. Michael ;
Hanley, David A. ;
Rao, D. Sudhaker ;
Miller, Paul D. ;
Woodson, Grattan C., III ;
Lindsay, Robert ;
Binkley, Neil ;
Wan, Xiaohai ;
Ruff, Valerie A. ;
Janos, Boris ;
Taylor, Kathleen A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (08) :2799-2808
[6]
Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women [J].
Drake, Matthew T. ;
Srinivasan, Bhuma ;
Moedder, Ulrike I. ;
Peterson, James M. ;
McCready, Louise K. ;
Riggs, B. Lawrence ;
Dwyer, Denise ;
Stolina, Marina ;
Kostenuik, Paul ;
Khosla, Sundeep .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (11) :5056-5062
[7]
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair [J].
Florio, Monica ;
Gunasekaran, Kannan ;
Stolina, Marina ;
Li, Xiaodong ;
Liu, Ling ;
Tipton, Barbara ;
Salimi-Moosavi, Hossein ;
Asuncion, Franklin J. ;
Li, Chaoyang ;
Sun, Banghua ;
Tan, Hong Lin ;
Zhang, Li ;
Han, Chun-Ya ;
Case, Ryan ;
Duguay, Amy N. ;
Grisanti, Mario ;
Stevens, Jennitte ;
Pretorius, James K. ;
Pacheco, Efrain ;
Jones, Heidi ;
Chen, Qing ;
Soriano, Brian D. ;
Wen, Jie ;
Heron, Brenda ;
Jacobsen, Frederick W. ;
Brisan, Emil ;
Richards, William G. ;
Ke, Hua Zhu ;
Ominsky, Michael S. .
NATURE COMMUNICATIONS, 2016, 7
[8]
Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength [J].
Fox, J. ;
Miller, M. A. ;
Newman, M. K. ;
Metcalfe, A. F. ;
Turner, C. H. ;
Recker, R. R. ;
Smith, S. Y. .
CALCIFIED TISSUE INTERNATIONAL, 2006, 79 (04) :262-272
[9]
Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans [J].
Fraher, LJ ;
Avram, R ;
Watson, PH ;
Hendy, GN ;
Henderson, JE ;
Chong, KL ;
Goltzman, D ;
Morley, P ;
Willick, GE ;
Whitfield, JF ;
Hodsman, AB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (08) :2739-2743
[10]
The Waning of Teriparatide Effect on Bone Formation Markers in Postmenopausal Osteoporosis Is Associated with Increasing Serum Levels of DKK1 [J].
Gatti, Davide ;
Viapiana, Ombretta ;
Idolazzi, Luca ;
Fracassi, Elena ;
Rossini, Maurizio ;
Adami, Silvano .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (05) :1555-1559